• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, December 11, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Cell Reports publishes data supporting the importance of ion channel, Kv7.2/7.3 as a target in ALS

Bioengineer by Bioengineer
June 8, 2021
in Chemistry
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Data supports QurAlis’ approach to treat hyperexcitability induced neurodegeneration in ALS patients; QurAlis gears up for clinical development of therapeutic candidate, QRL-101

CAMBRIDGE, Mass.–(BUSINESS WIRE)–QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports titled Human Amyotrophic Lateral Sclerosis Excitability Phenotype Screen: Target Discovery and Validation by QurAlis founders Kasper Roet, Ph.D., Clifford Woolf, M.D., Ph.D., and Kevin Eggan, Ph.D., who pioneered a high-content, live-cell imaging screen using ALS patient-derived motor neurons in combination with a compound library generated by Pfizer to identify drug targets to treat hyperexcitability induced neurodegeneration in ALS patients.

The publication describes a live-cell screening strategy targeting abnormal electrophysiological properties to reveal targets that modulate the intrinsic hyperexcitability of ALS motor neurons. This unbiased screen using human ALS motor neurons identified Kv7.2/7.3 as a strongly overrepresented drug target. Dysfunction of Kv7.2/7.3 in ALS motor neurons had been previously identified by Drs. Kevin Eggan, Clifford Woolf, Brian Wainger, and Evangelos Kiskinis, which led to the development of a precision medicine program at QurAlis to develop a selective Kv7.2/7.3 ion channel opener to treat ALS patients. The validity of Kv7.2/7.3 as a drug target for ALS patients was recently also strongly supported by results of a clinical study published in JAMA Neuro showing that Kv7 modulation can decrease spinal and cortical motor neuron excitability, both of which have been linked to patient survival. Through bioinformatic deconvolution, the screen, which was a concerted effort of scientists from the Boston Children’s Hospital, including shared first author Dr. Xuan Huang, The Harvard Stem Cell Institute, and the Pfizer Centers for Therapeutic Innovation also found AMPA receptors and D2 dopamine receptors as novel excitability modulating targets that contribute to ALS motor neuron excitability.

“These research results strengthen our hypothesis that the QurAlis selective Kv7.2/7.3 opener, QRL-101 (QRA-244), has the potential to be an effective therapy for patients suffering from hyperexcitability induced motor neuron degeneration,” said Kasper Roet, Ph.D., CEO and Founder of QurAlis. “Previous research has identified Kv7.2/7.3 as an ALS drug target and the unbiased nature of this screen further emphasizes the importance of Kv7.2/7.3 in ALS motor neuron dysfunction.”

“It is widely believed that by reducing motor neuron hyperexcitability in ALS patients, we may be able to slow the progression of the disease,” said Leonard van den Berg, M.D., Ph.D., Chairman of the European Network to Cure ALS. “This study shows that excitability phenotypic screening using patient derived motor neurons is a novel and powerful method for the identification of drug targets that act on abnormal excitability and offers the potential to produce more effective therapies with fewer side effects.”

###

Please refer to the Cell Reports publication for additional results from this study.

About Kv7.2/7.3 Ion Channel Openers

Kv7.2/7.3 is a hetero-tetrameric voltage-gated potassium channel in cell membranes which is encoded by KCNQ2 and KCNQ3. Kv7.2/7.3 is the dominant component of the neuronal M-current in human motor neurons, which stabilizes the membrane potential and controls neuronal excitability.1

Therapies that reduce abnormal electrical activity in the brain by activating or opening the Kv7.2/7.3 ion-channel show the potential to decrease spinal and cortical motor neuron excitability in patients with ALS and the potential to positively effect CMAP (compound muscle action potential) amplitude2, suggesting that this may be an effective therapeutic approach for patients suffering from hyperexcitability induced motor neuron degeneration.

About QRL-101 (QRA-244)

QRL-101 (QRA-244) is QurAlis’ lead drug candidate intended to treat motor neuron hyperexcitability-induced disease progression in ALS patients, which is estimated to be up to 50% of all ALS cases. A Kv7 opener, QRL-101 has been shown in preclinical studies to have strong potential to control motor neuron hyperexcitability induced excitotoxicity with significantly fewer side effects than other drug candidates. QurAlis plans to initiate first-in-human studies of QRL-101 at the end of 2021, or the beginning of 2022.

About QurAlis Corporation

QurAlis is applying precision medicine to advance a novel therapeutic pipeline for the treatment of amyotrophic lateral sclerosis (ALS) and other genetically validated neurodegenerative diseases. The QurAlis platform enables the design and development of drugs that act directly on disease-causing genetic alterations. We are advancing three antisense and small molecule programs addressing sub-forms of ALS that account for the majority of ALS patients. QurAlis is at the leading edge of neurodegenerative research and development. For more information, please visit http://www.quralis.com or follow us on Twitter @QurAlisCo.

Sources:

1 Ihara Y, Tomonoh Y, Deshimaru M, Zhang B, Uchida T, et al. (2016) Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations. PLOS ONE 11(2): e0150095. https://doi.org/10.1371/journal.pone.0150095

2 Wainger BJ, Macklin EA, Vucic S, et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78(2):186-196. doi:10.1001/jamaneurol.2020.4300

blank

Media Contact:

Sharon Correia

Executive Vice President

LaVoieHealthScience

[email protected]

Media Contact
Sharon Correia
[email protected]

Related Journal Article

https://www.businesswire.com/news/home/20210608005951/en/Cell-Reports-Publishes-Discovery-Data-Supporting-the-Importance-of-Ion-Channel-Kv7.27.3-as-a-Therapeutic-Target-in-ALS
http://dx.doi.org/10.1016/j.celrep.2021.109224

Tags: BiochemistryBiologyClinical TrialsMedicine/HealthneurobiologyNeurochemistryPharmaceutical ChemistryPharmaceutical Science
Share13Tweet8Share2ShareShareShare2

Related Posts

Image shows a laser beam in Gavin Morley’s lab probes the quantum properties of a diamond. Credit: Gavin Morley

New project will take a step towards answering whether gravity is quantum

December 11, 2023
THE HISTORY AND CHARACTERISTICS OF POLYMERIC NITROGEN SYNTHESIZED HITHERTO

Scientists used large scientific facilities to test the synthesis and characterization of polymeric nitrogen

December 11, 2023

A cool (temperature) take on direct air carbon capture

December 11, 2023

Chance twists ordered carbon nanotubes into ‘tornado films’

December 11, 2023
Please login to join discussion

POPULAR NEWS

  • Figure 1

    Understanding rapid tendon regeneration in newts may one day help human athletes

    86 shares
    Share 34 Tweet 22
  • Photonic chip that ‘fits together like Lego’ opens door to semiconductor industry

    36 shares
    Share 14 Tweet 9
  • Study finds increasingly popular oral nicotine pouches do little to curb smokers’ cravings

    35 shares
    Share 14 Tweet 9
  • One of the largest magnetic storms in history quantified: Aurorae covered much of the night sky from the Tropics to the Polar Regions

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Diabetes: examining microvasculature with AI and an optoacoustic skin scanner

Bee species in Wake County, N.C.: are they missing or just hard to find?

In 7 months, online Target ID course from AI drug discovery company Insilico Medicine surpasses 2,500 users

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 58 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In